Genmab A/s Share Price Today
(NASDAQ: GMAB)

Name: Genmab A/s Share Price Today (NASDAQ: GMAB) - Genmab A/s Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Genmab A/s share price is $24.1 & ₹2,095.95 as on 6 Mar 2025, 2.30 'hrs' IST

$24.1

▲

0.77

(3.3%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Genmab A/s share price in Dollar and Rupees. Guide to invest in Genmab A/s stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Genmab A/s, along with analyst recommendations, forecasts, and comprehensive financials.

Genmab A/s share price movements

Today's Low: $23.87
Today's High: $24.11
$24.10
0.98%
Downside
Day's Volatility :1.02%
Upside
0.04%
52 Weeks Low: $18.64
52 Weeks High: $31.88
$24.10
22.68%
Downside
52 Weeks Volatility :41.55%
Upside
24.4%

Genmab A/s (GMAB) Returns

Period	Genmab A/s	Sector (Health Care)	Index (Russel 2000)
3 Months	6.77%	2.1%	0.0%
6 Months	-15.75%	-4.1%	0.0%
1 Year	-19.16%	2.2%	0.0%
3 Years	-27.03%	11.8%	-11.6%

Genmab A/s (GMAB) Key Statistics

in dollars & INR

Previous Close	$23.33
Open	$23.98
Today's High	$24.11
Today's Low	$23.865
Market Capitalization	$14.6B
Today's Volume	$198.9K
52 Week High	$31.88
52 Week Low	$18.635
Revenue TTM	$21.5B
EBITDA	$7.4B
Earnings Per Share (EPS)	$1.71
PE Ratio	13.43
Profit Margin	36.44%
Quarterly Earnings Growth YOY	4.63%
Return On Equity TTM	22.97%

How to invest in Genmab A/s Stock (GMAB) from India?

It is very easy for Indian residents to invest directly in Genmab A/s from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Genmab A/s stock in both Indian Rupees (INR) and US Dollars (USD). Search for Genmab A/s or GMAB on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Genmab A/s or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Genmab A/s shares which would translate to 0.036 fractional shares of Genmab A/s as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Genmab A/s, in just a few clicks!

Returns in Genmab A/s (GMAB) for Indian investors in Rupees

The Genmab A/s stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Genmab A/s investment value today

Current value as on today

₹88,469

Returns

₹11,531

(-11.53%)

Returns from Genmab A/s Stock

₹16,493 (-16.49%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards Genmab A/s (GMAB)

92%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Genmab A/s Stock from India on INDmoney has increased by 92% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Genmab A/s

AllianceBernstein L.P.
2.35%
BlackRock Inc
0.66%
Citadel Advisors Llc
0.49%
Orbis Allan Gray Ltd
0.44%
Morgan Stanley - Brokerage Accounts
0.44%
Capital Research & Mgmt Co - Division 3
0.40%

Analyst Recommendation on Genmab A/s

Buy

61%Buy

29%Hold

9%Sell

Based on 31 Wall street analysts offering stock ratings for Genmab A/s(by analysts ranked 0 to 5 stars)

Based on 31 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Genmab A/s Stock (GMAB)

What analysts predicted

Upside of 42.69%

Target:

$34.39

Current:

$24.10

Insights on Genmab A/s Stock (Ticker Symbol: GMAB)

Price Movement
In the last 7 days, GMAB stock has moved up by 3.2%
Increasing Revenue
Revenue is up for the last 4 quarters, 4.14B → 6.44B (in $), with an average increase of 13.3% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, 1.26B → 3.84B (in $), with an average increase of 67.1% per quarter
GMAB vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 62.3% return, outperforming this stock by 81.2%
GMAB vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 47.7% return, outperforming this stock by 72.5%
Price to Sales
ForGMAB every $1 of sales, investors are willing to pay $0.7, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $13.8 for every $1 of sales.

GMAB Genmab A/s Financials in INR & Dollars

	FY19	Y/Y Change
Revenue	$798.0M	↑ 77.38%
Net Income	$322.1M	↑ 47.13%
Net Profit Margin	40.37%	↓ 8.29%

	FY20	Y/Y Change
Revenue	$1.7B	↑ 88.43%
Net Income	$777.7M	↑ 119.67%
Net Profit Margin	47.06%	↑ 6.69%

	FY21	Y/Y Change
Revenue	$1.3B	↓ 16.11%
Net Income	$449.5M	↓ 37.85%
Net Profit Margin	34.86%	↓ 12.2%

	FY22	Y/Y Change
Revenue	$2.1B	↑ 72.07%
Net Income	$775.6M	↑ 84.38%
Net Profit Margin	37.36%	↑ 2.5%

	FY23	Y/Y Change
Revenue	$2.4B	↑ 12.87%
Net Income	$637.3M	↓ 20.18%
Net Profit Margin	26.42%	↓ 10.94%

	FY24	Y/Y Change
Revenue	$21.5B	↑ 30.67%
Net Income	$7.8B	↑ 80.24%
Net Profit Margin	36.44%	↑ 10.02%

	Q3 FY23	Q/Q Change
Revenue	$679.2M	↑ 13.01%
Net Income	$304.8M	↑ 56.89%
Net Profit Margin	44.88%	↑ 12.56%

	Q4 FY23	Q/Q Change
Revenue	$685.1M	↓ 1.39%
Net Income	$93.7M	↓ 69.94%
Net Profit Margin	13.68%	↓ 31.2%

	Q1 FY24	Q/Q Change
Revenue	$603.9M	↓ 11.44%
Net Income	$193.1M	↑ 107.03%
Net Profit Margin	31.98%	↑ 18.3%

	Q2 FY24	Q/Q Change
Revenue	$779.3M	↑ 30.39%
Net Income	$203.1M	↑ 6.26%
Net Profit Margin	26.06%	↓ 5.92%

	Q3 FY24	Q/Q Change
Revenue	$5.5B	↑ 2.55%
Net Income	$1.3B	↓ 10.09%
Net Profit Margin	22.85%	↓ 3.21%

	Q4 FY24	Q/Q Change
Revenue	$6.4B	↑ 16.26%
Net Income	$3.8B	↑ 203.71%
Net Profit Margin	59.7%	↑ 36.85%

	FY19	Y/Y Change
Profit	$798.0M	↑ 77.38%

	FY20	Y/Y Change
Profit	$1.7B	↑ 88.43%

	FY21	Y/Y Change
Profit	$1.3B	↓ 16.11%

	FY22	Y/Y Change
Profit	$2.1B	↑ 72.07%

	FY23	Y/Y Change
Profit	$2.4B	↑ 11.33%

	FY24	Y/Y Change
Profit	$20.5B	↑ 26.42%

	Q3 FY23	Q/Q Change
Profit	$664.9M	↑ 10.62%

	Q4 FY23	Q/Q Change
Profit	$666.6M	↓ 1.98%

	Q1 FY24	Q/Q Change
Profit	$576.9M	↓ 13.05%

	Q2 FY24	Q/Q Change
Profit	$751.9M	↑ 31.68%

	Q3 FY24	Q/Q Change
Profit	$5.3B	↑ 1.06%

	Q4 FY24	Q/Q Change
Profit	$6.1B	↑ 15.89%

	FY19	Y/Y Change
Operating Cash Flow	$197.2M	↑ 30.67%
Investing Cash Flow	$-294.9M	↑ 11.53%
Financing Cash Flow	$544.3M	↓ 5262.13%

	FY20	Y/Y Change
Operating Cash Flow	$1.1B	↑ 385.14%
Investing Cash Flow	$-384.3M	↑ 18.56%
Financing Cash Flow	$11.6M	↓ 98.06%

	FY21	Y/Y Change
Operating Cash Flow	$338.7M	↓ 65.37%
Investing Cash Flow	$-146.1M	↓ 59.12%
Financing Cash Flow	$-63.8M	↓ 691.55%

	FY22	Y/Y Change
Operating Cash Flow	$556.5M	↑ 75.58%
Investing Cash Flow	$-392.8M	↑ 187.3%
Financing Cash Flow	$-112.2M	↑ 87.86%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$291.6M	↑ 367.2%
Investing Cash Flow	$144.3M	↓ 154.93%
Financing Cash Flow	$2.9M	↑ 185.71%

Genmab A/s Technicals Summary

Sell

Neutral

Buy

Genmab A/s is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Genmab A/s (GMAB) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Genmab A/s	21.45%	-15.75%	-19.16%	-27.03%	8.82%
Regeneron Pharmaceuticals, Inc.	1.3%	-41.29%	-30.51%	9.2%	42.38%
Beone Medicines Ltd	15.19%	34.31%	61.3%	43.16%	68.1%
Vertex Pharmaceuticals Incorporated	3.37%	3.77%	18.06%	106.43%	121.36%
Alnylam Pharmaceuticals, Inc.	-11.52%	-3.4%	62.32%	49.04%	120.93%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Genmab A/s	13.43	13.43	0.58	1.48	0.23	0.11	NA	577.54
Regeneron Pharmaceuticals, Inc.	17.85	17.85	1.03	43.09	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.43	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.33	18.07	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.57	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Genmab A/s	Buy	$14.6B	8.82%	13.43	36.44%
Regeneron Pharmaceuticals, Inc.	Buy	$74.9B	42.38%	17.85	31.07%
Beone Medicines Ltd	NA	$28.5B	68.1%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$124.1B	121.36%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$31.5B	120.93%	NA	-12.37%

About Genmab A/s

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Organization	Genmab A/s
Employees	2682
CEO	Dr. Jan G.J. van de Winkel Ph.D.
Industry	Health Technology

Management People of Genmab A/s

Name	Title
Dr. Jan G.J. van de Winkel Ph.D.	Co-Founder, President & CEO
Mr. Anthony Pagano CPA	Executive VP & CFO
Mr. Rayne Waller	Executive VP & Chief Technical Operations Officer
Ms. Birgitte Stephensen M.Sc.	Executive VP & Chief Legal Officer
Mr. Christopher Cozic	Executive VP & Chief People Officer
Dr. Martine J. van Vugt Ph.D.	Executive VP & Chief Strategy Officer
Mr. Martin Schultz	Senior Director of Clinical Operations & Non-Independent Director
Dr. Judith V. Klimovsky M.D.	Executive VP & Chief Development Officer
Dr. Tahamtan Ahmadi M.D., Ph.D.	Executive VP, Chief Medical Officer & Head of Experimental Medicines
Dr. Mijke Zachariasse Ph.D.	Senior Director, Head of Antibody Research Materials & Non-Independent Director

Important FAQs about investing in GMAB Stock from India :

What is Genmab A/s share price today?

Genmab A/s share price today stands at $24.10, Open: $23.98 ; Previous Close: $23.33 ; High: $24.11 ; Low: $23.87 ; 52 Week High: $31.88 ; 52 Week Low: $18.64.

The stock opens at $23.98, after a previous close of $23.33. The stock reached a daily high of $24.11 and a low of $23.87, with a 52-week high of $31.88 and a 52-week low of $18.64.

Can Indians buy Genmab A/s shares?

Yes, Indians can invest in the Genmab A/s (GMAB) from India.

With INDmoney, you can buy Genmab A/s at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Genmab A/s at zero transaction cost.

How can I buy Genmab A/s shares from India?

It is very easy to buy Genmab A/s from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Genmab A/s (GMAB) be purchased?

Yes, you can buy fractional shares of Genmab A/s with INDmoney app.

What are the documents required to start investing in Genmab A/s stocks?

To start investing in Genmab A/s, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.